Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.
Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading.
Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 150 points on Wednesday.
The Dow traded up 0.46% to 34,989.30 while the NASDAQ rose 0.16% to 14,116.28. The S&P 500 also rose, gaining, 0.26% to 4,507.40.
U.S. stocks traded higher this morning, with the Dow Jones gaining around 90 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.27% to 34,922.07 while the NASDAQ rose 0.36% to 14,144.63. The S&P 500 also rose, gaining, 0.27% to 4,507.75.